Tags

Type your tag names separated by a space and hit enter

BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons.
Obes Surg. 2011 Jan; 21(1):5-9.OS

Abstract

BACKGROUND

The BioEnterics® Intragastric Balloon (BIB®) is a well-established device for temporary treatment in morbidly obese patients. The aim of this study is the evaluation, in a population of 714 consecutive outpatient setting cases, BIB® results in terms of weight loss and comorbidity change.

METHODS

BIB® was positioned in all cases after diagnostic endoscopy. The device was inflated under direct endoscopic vision with saline solution (600-700 ml) and methylene blue (10 ml). Intubation was carried out in patients with body mass index (BMI) > 40 kg/m(2) affected by sleep apnea or chronic obstructive pulmonary disease. After 6 months, balloon removal was carried out, and patients were discharged with drug therapy and 1,000 kcal diet. More than 100 patients underwent a second consecutive balloon positioning. One month from the removal of the first BIB, patients were given a second BIB. Patients were followed up weekly. Mortality, complications and their treatment, postplacement symptoms, comorbidities, BMI, percentage of excess BMI loss (%EBL), and percentage of excess weight loss (%EWL) were considered. Data are expressed as mean ± standard deviation.

RESULTS

From June 1, 2005, to May 31, 2007, 714 patients underwent BIB® placement (143 males/571 females; mean age, 38.4 ± 16.1; mean BMI, 37.6 ± 5.7 kg/m(2); mean EW, 56.3 ± 27.1 kg). After 6 months, mean BMI was 31.1 ± 7.2, mean %EWL was 41.6 ± 21.8, mean BMI loss was 6.5 ± 12.7, and mean %EBL was 44.5 ± 22.6. Of 714 patients, 112 underwent a second BIB placement. At the time of the second balloon placement, mean BMI was 32.9 ± 6.7 kg/m(2); range was 31-51. After the second balloon removal, mean BMI was 30.3 ± 7.2.

CONCLUSIONS

BIB® treatment is a safe and effective procedure for weight reduction, without mortality and with very low morbidity rates even in nonhospitalized patients. A second balloon can also be positioned without difficulties, achieving good results after 12 months of treatment.

Authors+Show Affiliations

Department of Digestive and Endoscopy, Madrid Sanchinarro University Hospital, C/Padre Arrupe 89, Chalet, 28050 Madrid, Spain. clinicalwriter@ymail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20306153

Citation

Lopez-Nava, Gontrand, et al. "BioEnterics® Intragastric Balloon (BIB®). Single Ambulatory Center Spanish Experience With 714 Consecutive Patients Treated With One or Two Consecutive Balloons." Obesity Surgery, vol. 21, no. 1, 2011, pp. 5-9.
Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5-9.
Lopez-Nava, G., Rubio, M. A., Prados, S., Pastor, G., Cruz, M. R., Companioni, E., & Lopez, A. (2011). BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obesity Surgery, 21(1), 5-9. https://doi.org/10.1007/s11695-010-0093-3
Lopez-Nava G, et al. BioEnterics® Intragastric Balloon (BIB®). Single Ambulatory Center Spanish Experience With 714 Consecutive Patients Treated With One or Two Consecutive Balloons. Obes Surg. 2011;21(1):5-9. PubMed PMID: 20306153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. AU - Lopez-Nava,Gontrand, AU - Rubio,Miguel Angel, AU - Prados,Susana, AU - Pastor,Gabriela, AU - Cruz,Mar Rodriguez, AU - Companioni,Ena, AU - Lopez,Andres, Y1 - 2010/03/20/ PY - 2009/01/28/received PY - 2010/01/28/accepted PY - 2010/3/23/entrez PY - 2010/3/23/pubmed PY - 2011/4/7/medline SP - 5 EP - 9 JF - Obesity surgery JO - Obes Surg VL - 21 IS - 1 N2 - BACKGROUND: The BioEnterics® Intragastric Balloon (BIB®) is a well-established device for temporary treatment in morbidly obese patients. The aim of this study is the evaluation, in a population of 714 consecutive outpatient setting cases, BIB® results in terms of weight loss and comorbidity change. METHODS: BIB® was positioned in all cases after diagnostic endoscopy. The device was inflated under direct endoscopic vision with saline solution (600-700 ml) and methylene blue (10 ml). Intubation was carried out in patients with body mass index (BMI) > 40 kg/m(2) affected by sleep apnea or chronic obstructive pulmonary disease. After 6 months, balloon removal was carried out, and patients were discharged with drug therapy and 1,000 kcal diet. More than 100 patients underwent a second consecutive balloon positioning. One month from the removal of the first BIB, patients were given a second BIB. Patients were followed up weekly. Mortality, complications and their treatment, postplacement symptoms, comorbidities, BMI, percentage of excess BMI loss (%EBL), and percentage of excess weight loss (%EWL) were considered. Data are expressed as mean ± standard deviation. RESULTS: From June 1, 2005, to May 31, 2007, 714 patients underwent BIB® placement (143 males/571 females; mean age, 38.4 ± 16.1; mean BMI, 37.6 ± 5.7 kg/m(2); mean EW, 56.3 ± 27.1 kg). After 6 months, mean BMI was 31.1 ± 7.2, mean %EWL was 41.6 ± 21.8, mean BMI loss was 6.5 ± 12.7, and mean %EBL was 44.5 ± 22.6. Of 714 patients, 112 underwent a second BIB placement. At the time of the second balloon placement, mean BMI was 32.9 ± 6.7 kg/m(2); range was 31-51. After the second balloon removal, mean BMI was 30.3 ± 7.2. CONCLUSIONS: BIB® treatment is a safe and effective procedure for weight reduction, without mortality and with very low morbidity rates even in nonhospitalized patients. A second balloon can also be positioned without difficulties, achieving good results after 12 months of treatment. SN - 1708-0428 UR - https://www.unboundmedicine.com/medline/citation/20306153/BioEnterics®_intragastric_balloon__BIB®___Single_ambulatory_center_Spanish_experience_with_714_consecutive_patients_treated_with_one_or_two_consecutive_balloons_ L2 - https://dx.doi.org/10.1007/s11695-010-0093-3 DB - PRIME DP - Unbound Medicine ER -